Industry Voice

Beyond Awareness: Why Patient Experience Must Shape the Future of Clinical Research

Written by:
Alicia C. Staley, Chief Patient Officer, Medidata

Every October, as Breast Cancer Awareness Month brings renewed attention to screening and early detection, I receive several automated reminders from healthcare organizations telling me it’s time to schedule a mammogram. But there’s a problem. I had a bilateral mastectomy in January 2008.

I was first diagnosed with breast cancer in 2004 and again in 2008. Following my second diagnosis, I underwent major surgery to eliminate the cancer. I’ve been free of breast cancer ever since. Yet nearly nineteen years later, healthcare systems still send me reminders for a screening I no longer need, despite several notes back to them. I appreciate the intention behind these messages.

For me, an automated message becomes an unexpected reminder of two cancer diagnoses, years of treatment, and difficult decisions that significantly changed my life.
This experience exposes a larger problem. We have developed remarkable technologies to diagnose and treat disease, yet the systems supporting healthcare frequently lack a complete understanding of the people they serve.

That disconnect has implications well beyond routine care. It raises fundamental questions about how we design clinical research, what information we consider important, and whose experiences influence the decisions we make.

When I was first diagnosed in 2004, the landscape of breast cancer treatment was considerably different. Over the past two decades, molecular diagnostics, targeted therapies, immunotherapy, and precision medicine have fundamentally changed how we understand and treat breast cancer. HER2-targeted therapies have transformed outcomes for many patients. Antibody-drug conjugates are expanding treatment options, and immunotherapy has become an important treatment for selected patients with triple-negative disease.

These advances represent decades of scientific investment and the contributions of patients who participated in clinical trials, often without knowing whether the treatments being studied would benefit them personally.

Progress Does Not Mean Resolution

According to the National Cancer Institute, the five-year relative survival rate for women diagnosed with breast cancer is approximately 92%. That represents extraordinary progress, but the overall statistic conceals substantial differences in outcomes.
For women diagnosed with metastatic breast cancer, five-year relative survival is approximately 34%. The American Cancer Society estimates that 321,910 women in the United States will be diagnosed with invasive breast cancer in 2026, and 42,140 will die from the disease.

Those numbers should temper any temptation to view breast cancer as a disease for which the major scientific challenges have been resolved.
Treatment resistance, recurrence, metastatic progression, long-term treatment effects, and disparities in access and outcomes remain formidable challenges. Breast cancer is a collection of biologically distinct diseases, with different trajectories and treatment needs.
October brings tremendous visibility to breast cancer. That attention has helped mobilize support for research and care. Continued investment remains essential, particularly for people living with metastatic disease and those whose cancers do not respond to existing treatments.

Scientific investment must also be accompanied by a commitment to improving how effectively our research infrastructure incorporates what patients know about living with the diseases we are trying to treat.

My mammogram reminders illustrate the consequences of disconnected information in a remarkably personal way.

Design Research Around Lived Experience

Despite decades of investment in electronic health records and healthcare technology, patients continue to navigate systems that cannot reliably share or interpret their medical histories. They repeat information, reconcile conflicting records, and explain decisions that should already be documented.

These gaps create administrative burden, unnecessary anxiety, and potential safety risks when relevant clinical information is unavailable.  Clinical research faces similar challenges.

A participant’s medical history may be distributed across multiple institutions. Information about previous treatments, adverse events, and long-term outcomes may be difficult to access or reconcile. Research teams may understand a participant’s eligibility for a study without fully appreciating the cumulative burden of the treatments and healthcare experiences that preceded enrollment.  Interoperability and longitudinal data are essential to addressing these problems, provided information is shared appropriately and securely.

Yet comprehensive patient understanding requires another source of evidence: the patient’s lived experience.  Medical records document diagnoses, treatments, and clinical outcomes. Patients can explain what those treatments required of them, how adverse effects influenced daily life, which outcomes mattered most, and where care created avoidable hardship.

Together, clinical information and lived experience offer a more complete foundation for decisions. Their combined value becomes especially important when research teams are designing the studies that will determine future treatment options.
Alicia Staley

My experiences as a breast cancer survivor have profoundly shaped how I approach clinical research and drug development. Having spent decades navigating healthcare, I understand that decisions made in conference rooms during protocol development eventually become demands placed on patients’ lives.

A required clinic visit may represent several hours away from work, additional childcare expenses, or a physically exhausting journey during chemotherapy. An assessment that appears straightforward in a protocol may carry substantial emotional or physical consequences for someone managing advanced disease.

For a patient living with metastatic breast cancer, time spent traveling, waiting, or completing duplicative assessments carries particular significance.

These considerations should influence research design from the beginning.

The FDA’s Patient-Focused Drug Development guidance recognizes the value of systematically collecting patient experience data to inform medical product development. More recently, the updated ICH E6(R3) Good Clinical Practice guideline has reinforced the importance of quality by design, stakeholder perspectives, and avoiding unnecessary participant burden.

Our industry has an opportunity to translate these principles into consistent operational practice.  In my role as Chief Patient Officer at Medidata, I’ve seen how engaging patient advocates early in technology development reveals assumptions that product teams might otherwise overlook. Through our Patient Insights Board, patient advocates have participated in 65 design studios since 2020, contributing perspectives that have influenced eight product offerings.  These discussions help teams understand how a solution will function in the context of a patient’s actual life, allowing developers to identify challenges while meaningful design changes remain possible.

Put Patients at the Center of Protocol Development

Clinical trial protocols deserve the same scrutiny. Patients can help research teams evaluate whether eligibility criteria unnecessarily exclude certain populations, whether visit schedules are realistic, and whether study endpoints capture outcomes that matter to participants.

They can identify opportunities to simplify assessments, improve informed consent, reduce travel, and make participation more accessible.  Their insights are equally important for patient safety.

A protocol may be scientifically sound and still create burdens that affect adherence, compromise the quality of reported information, or make emerging symptoms difficult for participants to recognize and communicate.

Patients who have experienced treatment-related fatigue, cognitive changes, neuropathy, or other adverse effects can help researchers anticipate these challenges before a study begins.

Early engagement also requires representative perspectives. Someone with early-stage breast cancer may have different priorities from a person living with metastatic disease. Geographic, socioeconomic, racial, cultural, and treatment-related differences further shape patients’ experiences.

Meaningful patient involvement requires understanding those differences rather than assuming a small number of perspectives can represent an entire patient population.

Let Patient Engagement Direct Decision-Making

Most importantly, patient engagement must influence decisions.

If patient input identifies unnecessary visits, confusing assessments, or barriers to participation, research teams should document those findings, evaluate possible changes, and explain how the resulting protocol addresses them.

That is how lived experience becomes an operational component of research quality.

The clinical research industry has sophisticated systems for evaluating scientific validity, data integrity, regulatory compliance, and operational risk.

Patient experience deserves comparable discipline.

For sponsors, CROs, investigators, and technology providers, I propose three priorities to consider:

  1. Engage patients before protocols are finalized. Incorporate representative patient and caregiver perspectives during early planning, when eligibility criteria, endpoints, visit schedules, and assessment strategies can still be meaningfully influenced.
  2. Evaluate participant burden and safety together. Examine the cumulative demands of participation, including travel, financial strain, treatment effects, digital requirements, and the ability to recognize and report adverse events. Use those findings to improve protocols while preserving scientific rigor.
  3. Measure whether patient input changes research decisions. Document recommendations, resulting modifications, and the rationale when changes cannot be made. Evaluate whether those decisions improve participation, retention, accessibility, and the quality of the evidence generated.

These priorities should become part of how we define quality in clinical research.

Looking Ahead

After twenty-two years of breast cancer survivorship, I am profoundly grateful for the scientific advances that have transformed treatment possibilities. I’m equally conscious that many people diagnosed with breast cancer today still face tremendous uncertainty, limited options, and enormous burdens.

Breast Cancer Awareness Month provides an opportunity to recognize that progress, honor those we’ve lost, and renew our commitment to discovery.

For those of us working in clinical research, it should also prompt action. Before approving the next breast cancer protocol, we should be able to demonstrate whose lived experiences informed its design, what we learned from them, and what changed as a result.

References and Further Reading

  1. American Cancer Society. (2026). Key Statistics for Breast Cancer.
  2. National Cancer Institute. (2026). Survival Rates and Prognosis for Breast Cancer.
  3. American Cancer Society. Mammograms After Breast Cancer Surgery.
  4. U.S. Food and Drug Administration. (2022). Patient-Focused Drug Development: Methods to Identify What Is Important to Patients. Final Guidance for Industry, FDA Staff, and Other Stakeholders.
  5. International Council for Harmonisation / European Medicines Agency. (2025). ICH E6(R3) Guideline for Good Clinical Practice.
  6. Association of Clinical Research Organizations (ACRO). (2023). Comments on ICH E6(R3): Good Clinical Practice.

Subscribe for Updates

The Association of Clinical Research Organizations (ACRO) represents the leading clinical research and technology companies around the world. In our newsletter, we bring you updates on our work and the impact that we are having in advancing the global clinical research industry.

Contact Information(Required)
Please select if you're a member of the media.
Scroll to Top